A Phase 2, Randomised, Single-masked, Active-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Intravitreal THR-317 Administered in Combination With Ranibizumab, for the Treatment of Diabetic Macular Oedema (DME)

Trial Profile

A Phase 2, Randomised, Single-masked, Active-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Intravitreal THR-317 Administered in Combination With Ranibizumab, for the Treatment of Diabetic Macular Oedema (DME)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs THR 317 (Primary) ; Ranibizumab
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Sponsors ThromboGenics
  • Most Recent Events

    • 27 Apr 2018 Status changed from not yet recruiting to recruiting, according to a ThromboGenics media release.
    • 27 Apr 2018 According to a ThromboGenics media release, initial results are anticipated in Q3 2019.
    • 27 Apr 2018 According to a ThromboGenics media release, first patient has been enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top